This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooke, G. E. Articles by Leier, C. V. Search for Related Content PubMed PubMed Citation Articles by Cooke, G. E. Articles by Leier, C. V.

Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients

^a Division of Cardiology and The Heart and Lung Institute, Department of Internal Medicine, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, USA

View larger version (21K): [in a new window]   Figure 1 Severity of cardiac vasculopathy relative to time after cardiac transplantation. < = median.

View larger version (36K): [in a new window]   Figure 2 Lipid studies of the three patient groups and CAV subgroups. Open diamond = normal controls; closed square = control-ischemic; open square = control-dilated; open circle = non-CAV; closed circle = severe CAV; dotted line = normal value for laboratory; X = mild CAV; < = median. CAV = cardiac allograft vasculopathy; CHF = congestive heart failure; HDL = high-density lipoprotein.

View larger version (37K): [in a new window]   Figure 3 Plasma homocysteine levels and potential atherogenic peptides and proteins for the three patient groups and CAV subgroups. Open diamond = normal controls; closed square = control-ischemic; open square = control-dilated; open circle = non-CAV; closed circle = severe CAV; dotted line = normal value for laboratory; X = mild CAV; < = median. CAV = cardiac allograft vasculopathy; CHF = congestive heart failure.